ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
Question
ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
Direct answer
Upsized clinical biotech IPO pricing indicates receptive institutional demand for late-stage siRNA therapeutic pipelines. — bullish pressure on ADRX via debut secondary market liquidity and balance sheet capitalization.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-25
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share”, revision 1, evidence through 2026-09-25. https://marketontology.com/catalysts/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-initial-public-offering-at-17-per-sh-e9454a
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ADRX | ▲Bull | Intraday | debut secondary market liquidity and balance sheet capitalization | 54 |
ADARx Pharmaceuticals prices upsized $446.3M initial public offering at $17 per share
Upsized clinical biotech IPO pricing indicates receptive institutional demand for late-stage siRNA therapeutic pipelines. — bullish pressure on ADRX via debut secondary market liquidity and balance sheet capitalization.
Trading begins on Nasdaq on September 25, 2026 under ticker ADRX.
- SourceTrading begins on Nasdaq on September 25, 2026 under ticker ADRX.
- TransmissionUpsized clinical biotech IPO pricing indicates receptive institutional demand for late-stage siRNA therapeutic pipelines.
- SummaryADARx Pharmaceuticals raised $446.3 million in an upsized IPO priced at $17 per share. The company is developing late-stage siRNA therapeutics. Shares begin trading on Nasdaq under ticker ADRX today.
- ADRXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- ADRX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ADRX price vs. pre-event level
- ADRX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| ADRX | Bullishdisagreed | 19.35 2026-09-25 | +3.82% | -5.68% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering · news · 2026-09-24
Related catalysts
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M IPO at $17 per ShareADRX-5.68%
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX-5.68%
- 2026-09-25ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per shareADRX-5.68%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX XBI-3.04%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17ADRX-5.68%
- 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/ShareADRX-5.68%
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqADRX XBI-3.04%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.